Literature DB >> 19783150

Synthesis of fluorine-18 labeled rhodamine B: A potential PET myocardial perfusion imaging agent.

Tobias K Heinrich1, Vijay Gottumukkala, Erin Snay, Patricia Dunning, Frederic H Fahey, S Ted Treves, Alan B Packard.   

Abstract

There is considerable interest in developing an (18)F-labeled PET myocardial perfusion agent. Rhodamine dyes share several properties with (99m)Tc-MIBI, the most commonly used single-photon myocardial perfusion agent, suggesting that an (18)F-labeled rhodamine dye might prove useful for this application. In addition to being lipophilic cations, like (99m)Tc-MIBI, rhodamine dyes are known to accumulate in the myocardium and are substrates for Pgp, the protein implicated in MDR1 multidrug resistance. As the first step in determining whether (18)F-labeled rhodamines might be useful as myocardial perfusion agents for PET, our objective was to develop synthetic methods for preparing the (18)F-labeled compounds so that they could be evaluated in vivo. Rhodamine B was chosen as the prototype compound for development of the synthesis because the ethyl substituents on the amine moieties of rhodamine B protect them from side reactions, thus eliminating the need to include (and subsequently remove) protecting groups. The 2'-[(18)F]fluoroethyl ester of rhodamine B was synthesized by heating rhodamine B lactone with [(18)F]fluoroethyltosylate in acetonitrile at 165 degrees C for 30min using [(18)F]fluoroethyl tosylate, which was prepared by the reaction of ethyleneglycol ditosylate with Kryptofix 2.2.2, K(2)CO(3), and [(18)F]NaF in acetonitrile for 10min at 90 degrees C. The product was purified by semi-preparative HPLC to produce the 2'-[(18)F]fluoroethylester in >97% radiochemical purity with a specific activity of 1.3GBq/mumol, an isolated decay corrected yield of 35%, and a total synthesis time of 90min.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783150      PMCID: PMC2787817          DOI: 10.1016/j.apradiso.2009.08.013

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  20 in total

1.  Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis.

Authors:  T J Lampidis; Y Hasin; M J Weiss; L B Chen
Journal:  Biomed Pharmacother       Date:  1985       Impact factor: 6.529

2.  Photophysical, photochemical, and tumor-selectivity properties of bromine derivatives of rhodamine-123.

Authors:  Silvia H D Lacerda; Bindu Abraham; Thomas C Stringfellow; Guilherme L Indig
Journal:  Photochem Photobiol       Date:  2005 Nov-Dec       Impact factor: 3.421

3.  Absence of preferential uptake of [125I]iododihydrorhodamine 123 by four human tumor xenografts.

Authors:  B M Kinsey; A D Van den Abbeele; S J Adelstein; A I Kassis
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

4.  Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein.

Authors:  B De Moerloose; C Van de Wiele; C Dhooge; J Philippé; F Speleman; Y Benoit; G Laureys; R A Dierckx
Journal:  Eur J Nucl Med       Date:  1999-04

5.  In vivo studies of unlabeled and radioiodinated rhodamine-123.

Authors:  M M Vora; M Dhalla
Journal:  Int J Rad Appl Instrum B       Date:  1992-04

6.  Kinetic analysis of 18F-fluorodihydrorotenone as a deposited myocardial flow tracer: comparison to 201Tl.

Authors:  Robert C Marshall; Patricia Powers-Risius; Bryan W Reutter; James P O'Neil; Michael La Belle; Ronald H Huesman; Henry F VanBrocklin
Journal:  J Nucl Med       Date:  2004-11       Impact factor: 10.057

7.  Induction of the multixenobiotic/multidrug resistance system in various cell lines in response to perfluorinated carboxylic acids.

Authors:  Izabela Rusiecka; Andrzej C Składanowski
Journal:  Acta Biochim Pol       Date:  2008-06-14       Impact factor: 2.149

8.  [125I/127I/131I]Iodorhodamine: synthesis, cellular localization, and biodistribution in athymic mice bearing human tumor xenografts and comparison with [99mTc]hexakis(2-methoxyisobutylisonitrile).

Authors:  R S Harapanhalli; A M Roy; S J Adelstein; A I Kassis
Journal:  J Med Chem       Date:  1998-06-04       Impact factor: 7.446

9.  Synthesis and biological studies of iodinated (127/125I) derivatives of rhodamine 123.

Authors:  B M Kinsey; A I Kassis; F Fayad; W W Layne; S J Adelstein
Journal:  J Med Chem       Date:  1987-10       Impact factor: 7.446

10.  Selective retention of rhodamine-123 by malignant glioma in the rat.

Authors:  S K Powers; K Ellington
Journal:  J Neurooncol       Date:  1988-12       Impact factor: 4.130

View more
  12 in total

1.  Biodistribution and stability studies of [18F]fluoroethylrhodamine B, a potential PET myocardial perfusion agent.

Authors:  Vijay Gottumukkala; Tobias K Heinrich; Amanda Baker; Patricia Dunning; Frederic H Fahey; S Ted Treves; Alan B Packard
Journal:  Nucl Med Biol       Date:  2010-02-10       Impact factor: 2.408

2.  Biological characterization of F-18-labeled rhodamine B, a potential positron emission tomography perfusion tracer.

Authors:  Mark D Bartholomä; Huamei He; Christina A Pacak; Patricia Dunning; Frederic H Fahey; Francis X McGowan; Douglas B Cowan; S Ted Treves; Alan B Packard
Journal:  Nucl Med Biol       Date:  2013-09-04       Impact factor: 2.408

3.  New chemical and radiochemical routes to [18F]Rho6G-DEG-F, a delocalized lipophilic cation for myocardial perfusion imaging with PET.

Authors:  J A H Inkster; S Zhang; V Akurathi; A Belanger; S Dubey; T Treves; A B Packard
Journal:  Medchemcomm       Date:  2017-08-25       Impact factor: 3.597

4.  64Cu-labeled lissamine rhodamine B: a promising PET radiotracer targeting tumor mitochondria.

Authors:  Yang Zhou; Young-Seung Kim; Xin Yan; Orit Jacobson; Xiaoyuan Chen; Shuang Liu
Journal:  Mol Pharm       Date:  2011-05-24       Impact factor: 4.939

5.  (18)F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines.

Authors:  Mark D Bartholomä; Shaohui Zhang; Vamsidhar Akurathi; Christina A Pacak; Patricia Dunning; Frederic H Fahey; Douglas B Cowan; S Ted Treves; Alan B Packard
Journal:  Nucl Med Biol       Date:  2015-06-18       Impact factor: 2.408

6.  Effect of the prosthetic group on the pharmacologic properties of 18F-labeled rhodamine B, a potential myocardial perfusion agent for positron emission tomography (PET).

Authors:  Mark D Bartholomä; Vijay Gottumukkala; Shaohui Zhang; Amanda Baker; Patricia Dunning; Frederic H Fahey; S Ted Treves; Alan B Packard
Journal:  J Med Chem       Date:  2012-12-14       Impact factor: 7.446

7.  Direct fluorination of phenolsulfonphthalein: a method for synthesis of positron-emitting indicators for in vivo pH measurement.

Authors:  Alexander V Kachur; Anatoliy V Popov; Joel S Karp; E James Delikatny
Journal:  Cell Biochem Biophys       Date:  2013-05       Impact factor: 2.194

8.  Synthesis and Evaluation of (18)F-labeled Pyridaben Analogues for Myocardial Perfusion Imaging in Mice, Rats and Chinese mini-swine.

Authors:  Tiantian Mou; Zuoquan Zhao; Linyi You; Yesen Li; Qian Wang; Wei Fang; Jie Lu; Cheng Peng; Xianzhong Zhang
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

Review 9.  Mitochondrial-Targeted Molecular Imaging in Cardiac Disease.

Authors:  Jinhui Li; Jing Lu; You Zhou
Journal:  Biomed Res Int       Date:  2017-05-30       Impact factor: 3.411

10.  Synthesis of [18F]2B-SRF101: A Sulfonamide Derivative of the Fluorescent Dye Sulforhodamine 101.

Authors:  Ingrid Kreimerman; Williams Porcal; Silvia Olivera; Patricia Oliver; Eduardo Savio; Henry Engler
Journal:  Curr Radiopharm       Date:  2017-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.